Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01158456 · ClinicalTrials.gov registry record

Metabolism of NNK Among African Americans

A clinical trial of Lung Cancer, sponsored by Masonic Cancer Center, University of Minnesota.

Completed
Registry status
161
Enrollment target
1
Study location

NCT01158456 is a study of Lung Cancer that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 161 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01158456, a study of Lung Cancer, has completed, sponsored by Masonic Cancer Center, University of Minnesota.

COMPLETED
Registry status
161 participants
Enrollment target
1
Study location

Study Summary

Metabolism and DNA adduct formation are critical in cancer induction by NNK. The investigators goal is to understand whether the observed ethnic/racial differences in lung cancer incidence are due to variations in NNK metabolism. The investigators overall hypothesis is that cancer susceptibility relates to carcinogen dose and to the balance between carcinogen metabolic activation and detoxification. The investigators propose to test this hypothesis via investigation of potential differences in NNK metabolic activation and detoxification in African American and European American smokers.

Conditions Studied

Study Locations (1)

Minnesota

  • Tobacco Research Programs University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2010-12
Est. Completion 2017-11

What the Registry Record Tells You About NCT01158456

The ClinicalTrials.gov registry entry for NCT01158456 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT01158456 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01158456 about?

NCT01158456 is a clinical study titled "Metabolism of NNK Among African Americans". Metabolism and DNA adduct formation are critical in cancer induction by NNK. The investigators goal is to understand whether the observed ethnic/racial differences in lung cancer incidence are due to variations in NNK metabolism. The investigators overall hypothesis is that cancer susceptibility rel...

What is the current status of trial NCT01158456?

This trial is currently completed. The enrollment target is 161 participants. The study started on 2010-12. Estimated completion is 2017-11.

What conditions does trial NCT01158456 study?

This clinical trial studies the following conditions: Lung Cancer.

Who is sponsoring clinical trial NCT01158456?

This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01158456 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.